Rosuvastatin liposome encapsulated therapy (Beijing Inno Medicine)

N/A

Report date: 2026/04/30 20:00:20

Base Information

Drug NameRosuvastatin liposome encapsulated therapy (Beijing Inno Medicine)
Drug Alias NameYN001YN-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCD44 antigen inhibitorsHMG-CoA reductase inhibitors
TargetsCD44 antigenHMG-CoA reductase
Therapy Area/IndicationsAtherosclerosisCoronary Artery DiseaseCardiovascular Diseases +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Inno Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Inno Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsAtherosclerosisCoronary Artery DiseaseErectile Dysfunction +[4] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A